4D Molecular Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:FDMT) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 29.39 M45.86 M47.76 M43.38 M46.5 M 183.5 M Cash from investing activities -27.3 M-7.06 M31.95 M-13.85 M17.78 M 28.82 M Cash from financing activities 568 K601 K318.83 M17.25 M568 K — Free cash flow 27.61 M44.91 M47.13 M43.31 M46.59 M 181.94 M

Haberler

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBC Capital, 4D Molecular hissesi için Outperform notunu 32 dolar hedefle yineliyor

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

4D Molecular Therapeutics’in Finans Başkan Yardımcısı Ashoo Gupta FDMT hisselerinden 3.376 dolarlık satış yaptı

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aimei Health Technology (NASDAQ:AFJK), Aura Biosciences (NASDAQ:AURA)

Avago and Oracle among market cap stock movers on Wednesday

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential - Slideshow (NASDAQ:FDMT) 2025-12-17

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

4D Molecular Therapeutics’in hukuk müdürü 17 bin dolarlık hisse satışı gerçekleştirdi